Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Context Therapeutics Inc.

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics to Participate in Upcoming Investor Conferences in November
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers BCAB CNTX
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces $100 Million Private Placement
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics to Participate in Two August 2023 Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics to Participate in Two April 2023 Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.